グルコキナーゼ調節タンパク質小分子破壊剤の抗糖尿病効果
David J Lloyd1, David J St Jean2, Robert J M Kurzeja2
1Department of Metabolic Disorders, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, USA.
Nature
|November 15, 2013
まとめ
研究者らは,グルコキナーゼ調節タンパク質とグルコキナーゼの相互作用を妨害し,糖尿病を患っているネズミの血糖を正常化する新しい化合物を特定しました. このアプローチは,低血糖症のリスクが低下した2型糖尿病の治療の可能性を示しています.
科学分野:
- バイオケミストリー バイオケミストリー
- エンドクリノロジー エンドクリノロジー
- 薬理学 薬理学とは
背景:
- グルコースホメオスタシスは,高血糖症とII型糖尿病の予防に不可欠です.
- グルコースキナーゼ (GK) は,特に肝臓と臓のグルコースホメオスタシスを調節する.
- GKRPは,GKの活動を抑制し,断食中に無駄なグルコースサイクルを防止します.
研究 の 目的:
- GKRP-GK相互作用をターゲットにすることで,II型糖尿病のための新しい治療法を開発する.
- 直接的なGK活性化剤に関連する低血糖リスクを軽減するために.
主な方法:
- 小分子GK-GKRP破壊物質の識別と特徴付け (AMG-1694,AMG-3969)
- 糖尿病のネズミのモデルにおける化合物の有効性のインビトロおよびインビボ評価.
- AMG-1694.4で複合したGKRPの共結晶構造分析
主要な成果:
- AMG-1694とAMG-3969は,GKRP抑制を効果的に逆転させ,GK転位を促進しました.
- 化合物は,糖尿病を患っているネズミのモデルにおける血糖値を正常化する.
- 構造分析により,AMG-1694.4用の新しいGKRP結合ポケットが明らかになった.
- グルコースを下げる効果は,GK活性化剤とは異なり,糖尿病の動物に特異的であった.
結論:
- GKRPを阻害することは,II型糖尿病におけるグルコースを下げる治療のための新しいメカニズムを提供します.
- この戦略は,直接的なGK活性化剤と比較して低血糖症のリスクを低減することを示しています.
- 特定された化合物は,II型糖尿病管理のための有望な治療候補である.
関連する概念動画
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
958
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
958
Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Oral Hypoglycemic Agents: Glinides
1.0K
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Oral Hypoglycemic Agents: Biguanides and Glitazones
998
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
998
Hormones Regulating Blood Glucose
7.6K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
7.6K


